Mental Health DailyResearch. Evidence. Perspective.Published research on risperidone.
A 2026 analysis of 41 randomized studies involving 21,025 adults with schizophrenia found the largest estimated reductions in hostility and aggression for clozapine (standardized mean differ…
Read articleA 2026 randomized study involving 80 people with schizophrenia found that adding high-frequency repetitive transcranial magnetic stimulation to risperidone improved PANSS cognitive-factor sc…
Read articleA 2026 FAERS pharmacovigilance study of 28,938 dystonia reports found the strongest reporting signal for metoclopramide, while antipsychotics dominated the high-volume psychiatric medication…
Read articleA 2026 individual participant data meta-analysis of 1,721 dementia trial participants linked risperidone to cerebrovascular adverse events, HR 4.11 (95% CI 1.77 to 9.51), and major cardiovas…
Read articleMukai et al.’s 499-person Phase 2b schizophrenia trial tested whether higher, sustained PDE10A inhibition could turn MK-8189 into a non-D2 antipsychotic; it did not. At week 6, MK-8189 misse…
Read articleThe risperidone-stroke link in dementia is one of the longest-running safety signals in geriatric psychiatry, anchoring the FDA’s 2005 black-box warning on atypical antipsychotic mortality. …
Read articleSocial media has emerged as a pivotal source of real-world evidence, especially in understanding patient experiences and perceptions regarding the treatment of severe mental disorders such a…
Read article
